Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. He is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O'Neill is co-founder of Sitryx, which aims to develop new medicines for inflammatory diseases. Another company he co-founded, Inflazome was acquired by Roche in 2020 and is carrying out trials in Parkinson’s Disease, Severe Asthma and Heart disease using new therapeutics based on his work. He was awarded the Royal Dublin Society / Irish Times Boyle Medal for scientific excellence, the Royal Irish Academy Gold Medal for Life Sciences, the European Federation of Immunology Societies Medal and the Landsteiner Award from the Austrian Academy of Sciences. He is a member of the Royal Irish Academy, EMBO (European Molecular Biology Organisation) a Fellow of the Royal Society and holds Honorary Degrees from the Universities of Massachusetts and Bath.